---
title: "Eton Pharmaceuticals 在獲得 FDA 批准後股價上漲，但隨後漲幅收窄"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276935023.md"
description: "Eton Pharmaceuticals 的股票在 FDA 批准 Desmoda 用於治療中央性尿崩症後最初上漲，但隨後下跌了 1.5%，至 18 美元。該股票在公告後最高達到 19.98 美元。Eton 計劃於 3 月 9 日推出 Desmoda，預計年峯值銷售額為 3000 萬至 5000 萬美元"
datetime: "2026-02-25T20:41:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276935023.md)
  - [en](https://longbridge.com/en/news/276935023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276935023.md)
---

# Eton Pharmaceuticals 在獲得 FDA 批准後股價上漲，但隨後漲幅收窄

By Josh Beckerman

Shares of Eton Pharmaceuticals initially rose but pared their gains after the Food and Drug Administration approved Desmoda oral solution for management of central diabetes insipidus as antidiuretic replacement therapy.

Prior to a trading halt before the company's announcement, shares were at $17.69. The stock peaked at $19.98 Wednesday afternoon but was recently down 1.5% for the day at $18.

Eton expects a March 9 commercial launch for Desmoda, an oral liquid formulation of desmopressin. The company expects product peak sales of $30 million to $50 million annually.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 25, 2026 15:29 ET (20:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### 相關股票

- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [ETON.US](https://longbridge.com/zh-HK/quote/ETON.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)

## 相關資訊與研究

- [雙雙入選 2026 SGO 口頭報告：蘆康沙妥珠單抗 (sac-TMT) 兩項婦科腫瘤研究成果發佈](https://longbridge.com/zh-HK/news/282607157.md)
- [藥廠 AI 合作潮！諾和諾德攜手 OpenAI 股價走揚](https://longbridge.com/zh-HK/news/282755292.md)
- [鉅亨速報 - Factset 最新調查：阿里拉姆製藥 (ALNY-US) EPS 預估下修至 6.57 元，預估目標價為 447.00 元](https://longbridge.com/zh-HK/news/282708759.md)
- [諾和諾德夥 OpenAI 研發藥物 AI 分析數據 識別具潛力候選藥](https://longbridge.com/zh-HK/news/282661383.md)
- [諾和諾德與 OpenAI 攜手，以 AI 加速開發肥胖與代謝藥物](https://longbridge.com/zh-HK/news/282666368.md)